Case ReportsExtensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanomaPala, Laura; Conforti, Fabio; Cocorocchio, Emilia; Ferrucci, Pier FrancescoAuthor Information Division of Medical Oncology of Melanoma, Sarcoma and Rare tumors, European Institute of Oncology, IRCCS, Milan, Italy Received 24 November 2019 Revised form accepted 27 December 2019 Correspondence to Laura Pala, MD, Division of Medical Oncology of Melanoma, Sarcoma and Rare tumors, European Institute of Oncology, Milan, Italy, Tel: +390257489599; fax: +390294379319; e-mail: email@example.com Anti-Cancer Drugs: July 2020 - Volume 31 - Issue 6 - p 652-654 doi: 10.1097/CAD.0000000000000906 Buy Metrics Abstract Mucosal melanoma is rare and accounts for 1.3–1.4% of all melanomas. Kit mutations are found in approximately 15–20% of mucosal melanomas. Immunotherapy with anti cytotoxic T-lymphocyte associated protein 4 and antiprogrammed cell death protein 1 have reported low clinical efficacy in this melanoma subtype. Studies with Kit inhibitor Imatinib showed response rates ranging from 20 to 30%. We present the case of a patient with a c-kit mutated metastatic melanoma who developed autoimmune vitiligo during treatment with oral tyrosine kinase inhibitor Masitinib. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.